BioMarin Pharmaceutical Financials - Benzinga

BioMarin Pharmaceutical Inc

BMRNNASDAQ

Trade with Public

Trade with Public

$65.14

-1.56-2.34%

Last update: Aug 24, 1:05 PM

M&A: Alesta Therapeutics announced it will be acquired by BioMarin Pharmaceutical (BMRN) on Tuesday, August 18, 2026 for $275M

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

BioMarin Pharmaceutical Financials

BioMarin Pharmaceutical (BMRN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
BioMarin Pharmaceutical Raises FY2026 Adj EPS Guidance from $4.85-$5.05 to $4.90-$5.10 vs $3.64 Est; Raises FY2026 Sales Guidance from $3.825B-$3.925B to $3.875B-$3.925B vs $3.875B Est

BioMarin Pharmaceutical (NASDAQ:BMRN) raises FY2026 Adj EPS guidance from $4.85-$5.05 to $4.90-$5.10 vs $3.64 analyst estimate. Raises FY2026 sales outlook from $3.825 billion-$3.925 billion to $3.875 billion-$3.925

Benzinga Newsdesk

PRO
Biomarin Pharmaceutical Q2 Adj. EPS $1.20 Beats $0.69 Estimate, Sales $990.000M Beat $926.908M Estimate

Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $1.20 per share which beat the analyst consensus estimate of $0.69 by 73.91 percent. This is a 16.67 percent decrease over earnings of $1.44 per share

Benzinga Newsdesk

PRO
BioMarin Pharmaceutical Lowers FY2026 Adj EPS Guidance from $4.95-$5.15 to $4.85-$5.05 vs $4.43 Est; Raises FY2026 Sales Guidance from $3.325B-$3.425B to $3.825B-$3.925B vs $3.635B Est

Benzinga Newsdesk

PRO
Biomarin Pharmaceutical Q1 Adj. EPS $0.76 Misses $0.79 Estimate, Sales $766.208M Beat $755.610M Estimate

Benzinga Newsdesk

Earnings Scheduled For May 4, 2026

Benzinga Insights

PRO
BioMarin Pharmaceutical Sees FY2026 Sales $3.325B-$3.425B vs $3.507B Est

BioMarin Pharmaceutical (NASDAQ:BMRN) sees FY2026 sales of $3.325 billion-$3.425 billion vs $3.507 billion analyst estimate.

Benzinga Newsdesk